These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 37316234)

  • 1. Invasive meningococcal disease epidemiology and vaccination strategies in four Southern European countries: a review of the available data.
    Zografaki I; Detsis M; Del Amo M; Iantomasi R; Maia A; Montuori EA; Mendez C
    Expert Rev Vaccines; 2023; 22(1):545-562. PubMed ID: 37316234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccines against Neisseria meningitidis serogroup B strains - What does genomics reveal on the Portuguese strain's coverage.
    Bettencourt C; Nogueira P; Paulo Gomes J; João Simões M
    Vaccine; 2022 Aug; 40(33):4772-4779. PubMed ID: 35778280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimated strain coverage of serogroup B meningococcal vaccines: A retrospective study for disease and carrier strains in Greece (2010-2017).
    Tzanakaki G; Xirogianni A; Tsitsika A; Clark SA; Kesanopoulos K; Bratcher HB; Papandreou A; Rodrigues CMC; Maiden MCJ; Borrow R; Tsolia M
    Vaccine; 2021 Mar; 39(11):1621-1630. PubMed ID: 33597116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 'Be on the TEAM' Study (Teenagers Against Meningitis): protocol for a controlled clinical trial evaluating the impact of 4CMenB or MenB-fHbp vaccination on the pharyngeal carriage of meningococci in adolescents.
    Carr J; Plested E; Aley P; Camara S; Davis K; MacLennan JM; Gray S; Faust SN; Borrow R; Christensen H; Trotter C; Maiden MCJ; Finn A; Snape MD;
    BMJ Open; 2020 Oct; 10(10):e037358. PubMed ID: 33093030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Introduction of a second MenB vaccine into Europe - needs and opportunities for public health.
    Findlow J; Nuttens C; Kriz P
    Expert Rev Vaccines; 2019 Mar; 18(3):225-239. PubMed ID: 30821535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole genome analysis of Neisseria meningitidis isolates from invasive meningococcal disease collected in the Czech Republic over 28 years (1993-2020).
    Honskus M; Krizova P; Okonji Z; Musilek M; Kozakova J
    PLoS One; 2023; 18(3):e0282971. PubMed ID: 36913385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential Coverage of the 4CMenB Vaccine against Invasive Serogroup B
    Mulhall RM; Bennett D; Cunney R; Borrow R; Lucidarme J; Findlow J; Jolley KA; Bray J; Maiden MCJ; Moschioni M; Serino L; Stella M; Medini D
    mSphere; 2018 Aug; 3(4):. PubMed ID: 30135218
    [No Abstract]   [Full Text] [Related]  

  • 8. Broad vaccine protection against Neisseria meningitidis using factor H binding protein.
    Findlow J; Bayliss CD; Beernink PT; Borrow R; Liberator P; Balmer P
    Vaccine; 2020 Nov; 38(49):7716-7727. PubMed ID: 32878710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling the public health impact of different meningococcal vaccination strategies with 4CMenB and MenACWY versus the current toddler MenACWY National Immunization Program in Chile.
    Graña MG; Cavada G; Vasquez M; Shen J; Maervoet J; Klint J; Gómez JA
    Hum Vaccin Immunother; 2021 Dec; 17(12):5603-5613. PubMed ID: 34890520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 4CMenB journey to the 10-year anniversary and beyond.
    Abitbol V; Martinón-Torres F; Taha MK; Nolan T; Muzzi A; Bambini S; Borrow R; Toneatto D; Serino L; Rappuoli R; Pizza M
    Hum Vaccin Immunother; 2024 Dec; 20(1):2357924. PubMed ID: 38976659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Culture-Confirmed Invasive Meningococcal Disease in Canada, 2010 to 2014: Characterization of Serogroup B
    Tsang RSW; Law DKS; De Paola R; Giuliani M; Stella M; Zhou J; Deng S; Boccadifuoco G; Giuliani MM; Serino L
    mSphere; 2020 Mar; 5(2):. PubMed ID: 32132156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular characterization of invasive
    Sereikaitė E; Plepytė R; Petrutienė A; Stravinskienė D; Kučinskaitė-Kodzė I; Gėgžna V; Ivaškevičienė I; Žvirblienė A; Plečkaitytė M
    Front Cell Infect Microbiol; 2023; 13():1136211. PubMed ID: 36875527
    [No Abstract]   [Full Text] [Related]  

  • 13. A review of the immunogenicity, safety and current recommendations for the meningococcal serogroup B vaccine, MenB-FHbp.
    Burman C; Alderfer J; Snow VT
    J Clin Pharm Ther; 2020 Apr; 45(2):270-281. PubMed ID: 31820483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic Diversity of Meningococcal Serogroup B Vaccine Antigens among Carriage Isolates Collected from Students at Three Universities in the United States, 2015-2016.
    Marjuki H; Chang HY; Topaz N; Whaley MJ; Vuong J; Chen A; Jenkins LT; Hu F; Schmink S; Retchless AC; Thomas JD; Acosta AM; McNamara LA; Soeters HM; Mbaeyi S; Wang X
    mBio; 2021 May; 12(3):. PubMed ID: 34006659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neisseria meningitidis serogroup B carriage by adolescents and young adults living in Milan, Italy: Prevalence of strains potentially covered by the presently available meningococcal B vaccines.
    Terranova L; Principi N; Bianchini S; Di Pietro G; Umbrello G; Madini B; Esposito S
    Hum Vaccin Immunother; 2018 May; 14(5):1070-1074. PubMed ID: 29584565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methods to evaluate serogroup B meningococcal vaccines: From predictions to real-world evidence.
    Borrow R; Taha MK; Giuliani MM; Pizza M; Banzhoff A; Bekkat-Berkani R
    J Infect; 2020 Dec; 81(6):862-872. PubMed ID: 32745637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of invasive meningococcal disease case isolates in Atlantic Canada, 2014 to 2020: spatial-temporal variations of clones and predicted meningococcal B vaccine coverage.
    Tsang RSW; Law DKS; Zhou J; Haldane D; Garceau R; Zahariadis G; Mead K; Alexander D
    J Med Microbiol; 2022 Dec; 71(12):. PubMed ID: 36748536
    [No Abstract]   [Full Text] [Related]  

  • 18. Genetic Features of a Representative Panel of 110 Meningococcal B Isolates to Assess the Efficacy of Meningococcal B Vaccines.
    Muzzi A; Bodini M; Topaz N; Masignani V; Vadivelu K; Marjuki H; Wang X; Serino L; Medini D
    mSphere; 2022 Oct; 7(5):e0038522. PubMed ID: 36129279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular characterization of invasive serogroup B Neisseria meningitidis isolates from Spain during 2015-2018: Evolution of the vaccine antigen factor H binding protein (FHbp).
    Abad R; García-Amil C; Navarro C; Martín E; Martín-Díaz A; Vázquez JA
    J Infect; 2021 Apr; 82(4):37-44. PubMed ID: 33610688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics of a new meningococcal serogroup B vaccine, bivalent rLP2086 (MenB-FHbp; Trumenba®).
    Gandhi A; Balmer P; York LJ
    Postgrad Med; 2016 Aug; 128(6):548-56. PubMed ID: 27467048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.